230 related articles for article (PubMed ID: 32401547)
1. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
Barra F; Vitale SG; Seca M; Scala C; Leone Roberti Maggiore U; Cianci A; Ferrero S
Expert Opin Pharmacother; 2020 Aug; 21(12):1419-1430. PubMed ID: 32401547
[TBL] [Abstract][Full Text] [Related]
2. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
[TBL] [Abstract][Full Text] [Related]
3. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
[TBL] [Abstract][Full Text] [Related]
4. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
[TBL] [Abstract][Full Text] [Related]
5. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
6. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; A R S; Al Hendy A
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
[TBL] [Abstract][Full Text] [Related]
7. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids.
Stewart EA; Archer DF; Owens CD; Barnhart KT; Bradley LD; Feinberg EC; Gillispie-Bell V; Imudia AN; Liu R; Kim JH; Al-Hendy A
J Womens Health (Larchmt); 2022 May; 31(5):698-705. PubMed ID: 34582715
[No Abstract] [Full Text] [Related]
8. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas.
Dababou S; Garzon S; Laganà AS; Ferrero S; Evangelisti G; Noventa M; D'Alterio MN; Palomba S; Uccella S; Franchi M; Barra F
Expert Opin Investig Drugs; 2021 Sep; 30(9):903-911. PubMed ID: 34278887
[TBL] [Abstract][Full Text] [Related]
9. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.
Lynch SE; Mayer DC
Ann Pharmacother; 2022 Jan; 56(1):93-101. PubMed ID: 33998300
[TBL] [Abstract][Full Text] [Related]
10. Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Uterine Myomas: A Systematic Review and Network Meta-analysis of Efficacy Parameters and Adverse Effects.
Telek SB; Gurbuz Z; Kalafat E; Ata B
J Minim Invasive Gynecol; 2022 May; 29(5):613-625. PubMed ID: 34942350
[TBL] [Abstract][Full Text] [Related]
11. Elagolix: First Global Approval.
Lamb YN
Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
[TBL] [Abstract][Full Text] [Related]
12. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.
Muhammad J; Yusof Y; Ahmad I; Norhayati MN
BMC Womens Health; 2022 Jan; 22(1):14. PubMed ID: 35033041
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of elagolix in the treatment of endometriosis.
Perricos A; Wenzl R
Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
[TBL] [Abstract][Full Text] [Related]
14. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas: A Randomized Controlled Trial.
Brown E; Kroll R; Li H; Ng J; Pinsky B; Rodriguez JW; Thomas J; Snabes MC
Obstet Gynecol; 2023 Nov; 142(5):1068-1076. PubMed ID: 37769311
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.
Beck D; Winzenborg I; Liu M; Degner J; Mostafa NM; Noertersheuser P; Shebley M
Clin Pharmacokinet; 2022 Apr; 61(4):577-587. PubMed ID: 34878624
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Bradley L; Owens CD; Wang H; Barnhart KT; Feinberg E; Schlaff WD; Puscheck EE; Wang A; Gillispie V; Hurtado S; Muneyyirci-Delale O; Archer DF; Carr BR; Simon JA; Stewart EA
Am J Obstet Gynecol; 2021 Jan; 224(1):72.e1-72.e50. PubMed ID: 32702363
[TBL] [Abstract][Full Text] [Related]
18. Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment.
Ng J; Duan WR; Marbury T; Schmidt JM; Klein CE
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1053-1061. PubMed ID: 30570832
[TBL] [Abstract][Full Text] [Related]
19. Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women.
Archer DF; Ng J; Chwalisz K; Chiu YL; Feinberg EC; Miller CE; Feldman RA; Klein CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31650182
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
